1. Blüher M. Obesity: global epidemiology and pathogenesis. Nature reviews Endocrinology. 2019;15(5):288-98. [DOI:10.1038/s41574-019-0176-8]

2. Nour TY, Altintaş KH. Effect of the COVID-19 pandemic on obesity and it is risk factors: a systematic review. BMC public health. 2023;23(1):1018. [DOI:10.1186/s12889-023-15833-2]

3. Dhawan D SS. Abdominal Obesity, Adipokines and Non-communicable Diseases. The Journal of steroid biochemistry and molecular biology. 2020. [DOI:10.1016/j.jsbmb.2020.105737]

4. Whitlock G LS, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (London, England). Lancet (London, England). 2009.

5. Bays HE, Gonsahn-Bollie S, Younglove C, Wharton S. Obesity Pillars Roundtable: Body mass index and body composition in Black and Female individuals. Race-relevant or racist? Sex-relevant or sexist? Obesity Pillars (Online). 2022;4:100044. [DOI:10.1016/j.obpill.2022.100044]

6. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. [DOI:10.1172/JCI23606]

7. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235-53. [DOI:10.1038/nrd2792]

8. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426-37. [DOI:10.1016/j.cmet.2007.05.002]

9. Epperlein S, Gebhardt C, Rohde K, Chakaroun R, Patt M, Schamarek I, et al. The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits. Biomedicines. 2021;9(4). [DOI:10.3390/biomedicines9040345]

10. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415-25. [DOI:10.1016/j.cmet.2007.05.003]

11. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett. 2008;582(27):3805-10. [DOI:10.1016/j.febslet.2008.10.021]

12. Erickson A, Moreau R. The regulation of FGF21 gene expression by metabolic factors and nutrients. Horm Mol Biol Clin Investig. 2016;30(1). [DOI:10.1515/hmbci-2016-0016]

13. Tanimura Y, Aoi W, Takanami Y, Kawai Y, Mizushima K, Naito Y, et al. Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation. Physiol Rep. 2016;4(12). [DOI:10.14814/phy2.12828]

14. Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, et al. FGF21 and the late adaptive response to starvation in humans. J Clin Invest. 2015;125(12):4601-11. [DOI:10.1172/JCI83349]

15. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71(3):369-75. [DOI:10.1111/j.1365-2265.2008.03502.x]

16. Lundsgaard AM, Fritzen AM, Sjøberg KA, Myrmel LS, Madsen L, Wojtaszewski JFP, et al. Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. Mol Metab. 2017;6(1):22-9. [DOI:10.1016/j.molmet.2016.11.001]

17. Prida E, Álvarez-Delgado S, Pérez-Lois R, Soto-Tielas M, Estany-Gestal A, Fernø J, et al. Liver brain interactions: focus on FGF21 a systematic review. International journal of molecular sciences. 2022;23(21):13318. [DOI:10.3390/ijms232113318]

18. von Holstein-Rathlou S, BonDurant LD, Peltekian L, Naber MC, Yin TC, Claflin KE, et al. FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver. Cell Metab. 2016;23(2):335-43. [DOI:10.1016/j.cmet.2015.12.003]

19. Baruch A, Wong C. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans. 2020;117(46):28992-9000. [DOI:10.1073/pnas.2012073117]

20. Talukdar S, Owen BM, Song P, Hernandez G, Zhang Y, Zhou Y, et al. FGF21 Regulates Sweet and Alcohol Preference. Cell Metab. 2016;23(2):344-9. [DOI:10.1016/j.cmet.2015.12.008]

21. Ameka M, Markan KR. Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure. 2019;9(1):630. [DOI:10.1038/s41598-018-37198-y]

22. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670-7. [DOI:10.1016/j.cmet.2014.07.012]

23. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55(9):2319-26. [DOI:10.1007/s00125-012-2598-x]

24. Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell reports Medicine. 2020;1(4):100057. [DOI:10.1016/j.xcrm.2020.100057]

25. Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet (London, England). 2019;392(10165):2705-17. [DOI:10.1016/S0140-6736(18)31785-9]

26. Flippo KH, Potthoff MJ. Metabolic Messengers: FGF21. 2021;3(3):309-17. [DOI:10.1038/s42255-021-00354-2]

27. Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Möhlig M, Mai K, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36(1):145-9. [DOI:10.2337/dc12-0703]

28. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456-63. [DOI:10.1053/j.gastro.2010.04.054]

29. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246-53. [DOI:10.2337/db07-1476]

30. Olszanecka-Glinianowicz M, Madej P, Wdowczyk M, Owczarek A, Chudek J. Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome. European journal of endocrinology. 2015;172(2):173-9. [DOI:10.1530/EJE-14-0539]

31. Kang YE, Kim JT, Lim MA, Oh C, Liu L, Jung SN, et al. Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. Cancers (Basel). 2019;11(8). [DOI:10.3390/cancers11081154]

32. Oflazoglu U, Caglar S, Yılmaz HE, Önal HT, Varol U, Salman T, et al. The relationship between sarcopenia detected in newly diagnosed colorectal cancer patients and FGF21, irisin and CRP levels. European geriatric medicine. 2022;13(4):795-803. [DOI:10.1007/s41999-022-00635-3]

33. Roh E, Hwang SY, Yoo HJ, Baik SH, Cho B, Park YS, et al. Association of plasma FGF21 levels with muscle mass and muscle strength in a national multicentre cohort study: Korean Frailty and Aging Cohort Study. Age and ageing. 2021;50(6):1971-8. [DOI:10.1093/ageing/afab178]

34. Jung HW, Park JH, Kim DA, Jang IY, Park SJ, Lee JY, et al. Association between serum FGF21 level and sarcopenia in older adults. Bone. 2021;145:115877. [DOI:10.1016/j.bone.2021.115877]

35. Baker JF, Katz P, Weber DR, Gould P, George MD, Long J, et al. Adipocytokines and Associations With Abnormal Body Composition in Rheumatoid Arthritis. Arthritis Care & Research. 2023;75(3):616-24. [DOI:10.1002/acr.24790]

36. Bag Soytas R, Suzan V, Arman P, Emiroglu Gedik T, Unal D, Cengiz M, et al. Association of FGF-19 and FGF-21 levels with primary sarcopenia. Geriatr Gerontol Int. 2021;21(10):959-62. [DOI:10.1111/ggi.14263]

37. Gould PW, Zemel BS, Taratuta EG, Baker JF. Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations With Disease Characteristics, Body Composition, and Physical Functioning. J Rheumatol. 2021;48(4):504-12. [DOI:10.3899/jrheum.200673]

38. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191-4. [DOI:10.1001/jama.2013.281053]

39. Vasheghani-Farahani A, Tahmasbi M, Asheri H, Ashraf H, Nedjat S, Kordi R. The Persian, last 7-day, long form of the International Physical Activity Questionnaire: translation and validation study. Asian J Sports Med. 2011;2(2):106-16. [DOI:10.5812/asjsm.34781]

40. Porflitt-Rodríguez M, Guzmán-Arriagada V, Sandoval-Valderrama R, Tam CS, Pavicic F, Ehrenfeld P, et al. Effects of aerobic exercise on fibroblast growth factor 21 in overweight and obesity. A systematic review. Metabolism: clinical and experimental. 2022;129:155137. [DOI:10.1016/j.metabol.2022.155137]

41. Karami M, Mehrabi F, Allameh A, Pahlevan Kakhki M, Amiri M, Emami Aleagha MS. Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis. Journal of the neurological sciences. 2017;381:305-7. [DOI:10.1016/j.jns.2017.09.012]

42. Zhang Y, Jiang L, Su P, Ma Z, Kang W, Ye X, et al. Association between Plasma FGF21 Levels and Body Composition in Patients with Gastric Cancer. Nutrition and Cancer. 2022;75(1):349-56. [DOI:10.1080/01635581.2022.2118322]

43. Hanks LJ, Casazza K, Ashraf AP, Wallace S, Gutiérrez OM. Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females. Clin Endocrinol (Oxf). 2015;82(4):550-6. [DOI:10.1111/cen.12552]

44. Gijbels A, Schutte S, Esser D, Michielsen C, Siebelink E, Mars M. Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction: Secondary Analysis of an RCT. 2022;14(23). [DOI:10.3390/nu14235061]

45. Coppage AL, Heard KR, DiMare MT, Liu Y, Wu W, Lai JH, et al. Human FGF-21 Is a Substrate of Fibroblast Activation Protein. PloS one. 2016;11(3):e0151269. [DOI:10.1371/journal.pone.0151269]

46. Lewis JE, Ebling FJP, Samms RJ, Tsintzas K. Going Back to the Biology of FGF21: New Insights. Trends in endocrinology and metabolism: TEM. 2019;30(8):491-504. [DOI:10.1016/j.tem.2019.05.007]